


Spantide II

Cat. No.:	HY-P1722
CAS No.:	129176-97-2
Molecular Formula:	C ₈₆ H ₁₀₄ Cl ₂ N ₁₈ O ₁₃
Molecular Weight:	1668.76
Target:	Neurokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (59.92 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	0.5992 mL	2.9962 mL	5.9925 mL
5 mM	0.1198 mL	0.5992 mL	1.1985 mL
10 mM	0.0599 mL	0.2996 mL	0.5992 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Spantide II, an undecapeptide substance P (SP) analog, is a potent neurokinin-1 receptor (NK-1R) antagonist. Spantide II binds with NK-1R and blocks proinflammatory activities associated with SP. Spantide II can be used in the research of inflammatory skin disorders, such as psoriasis and contact dermatitis^{[1][2][3]}.

IC₅₀ & Target

NK1

REFERENCES

[1]. Xu XJ, et al. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. *Neuroscience*. 1991;42(3):731-7.

[2]. Kikwai L, et al. In vitro and in vivo evaluation of topical formulations of spantide II. *AAPS PharmSciTech*. 2005 Oct 31;6(4):E565-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA